OVARIAN NEOPLASMS

This study tests a new drug, LY3537982, in people with advanced solid tumors that have a specific genetic change called KRAS G12C. The goal is to see if the drug is safe and shrinks tumors. About 540 adults with lung, colon, endometrial, ovarian, pancreatic, or bile duct cancers …

This early-phase study tests a new daily pill, NKT3964, that breaks down a protein called CDK2 to slow cancer growth. It is for adults with advanced solid tumors (like ovarian, endometrial, breast, gastric, or lung cancer) that have not responded to standard treatments. The study…

This study tests a new targeted therapy, sacituzumab tirumotecan (Sac-TMT), given alone or with bevacizumab after initial chemotherapy for advanced ovarian cancer. About 900 participants will receive either the new treatment or standard care to see if it delays cancer growth. The…

This early-phase study tests a new treatment called TNhYP218 CAR T cells for people with solid tumors, including mesothelioma, that have returned or spread after standard therapy. The treatment uses a patient's own immune cells, modified in a lab to recognize and attack cancer ce…

This early-stage trial tests a drug called sigvotatug vedotin, alone or with other medicines, in people with advanced solid tumors like lung, head and neck, or breast cancer. The goal is to find a safe dose and check for side effects. About 1,000 participants will join this study…

This study tests a new drug, BMS-986340, alone or with other cancer treatments (nivolumab or docetaxel) in people with advanced solid tumors that have worsened after standard therapy. The goal is to find safe doses and understand side effects. About 949 adults with various cancer…

This trial tests a new drug called UCB4594, an antibody that targets a protein (HLA-G) found on many cancer cells. The goal is to see if it helps the immune system attack tumors. It is for people with advanced solid tumors (like lung, breast, or colon cancer) that have not respon…

This trial tests whether a combination of two drugs, vemurafenib and cobimetinib, can shrink or control rare cancers that have a specific BRAF V600 mutation. The drugs are already approved for melanoma, and researchers want to see if they help people with other cancer types, like…

This trial tests two drugs, trastuzumab and pertuzumab, already approved for breast cancer, in people with rare cancers that have a specific genetic change called HER2 amplification or mutation. About 30 adults and children with various rare cancers will receive the drug combinat…

This study tests a new type of CAR T cell therapy for adults with advanced solid tumors, including colorectal, pancreatic, lung, ovarian, and mesothelioma cancers. The therapy uses a patient's own immune cells, modified to recognize and attack cancer cells that have lost a specif…

This study offers ongoing access to the drug niraparib for people with ovarian or breast cancer who have already been taking it in a previous study and are still benefiting. The main goal is to monitor long-term safety and side effects. About 30 participants will continue treatme…

This study tests whether the immunotherapy drug dostarlimab, given alone or with bevacizumab, works better than standard chemotherapy for people with recurrent gynecological clear cell carcinoma (a rare cancer of the ovary, uterus, cervix, vagina, or vulva). About 198 participant…

This early-phase study tests a new drug called DM002 in about 160 people with advanced solid tumors (ovarian, prostate, endometrial, colorectal, or other solid cancers). The study has two parts: first, finding a safe dose by giving small groups gradually higher doses; second, giv…

This early-stage study tests a new drug called LY4337713 in people with advanced cancers (like pancreatic, breast, ovarian, or colorectal) that have high levels of a protein called FAP. The drug delivers radiation directly to cancer cells. The main goals are to check safety, find…

This early-stage study tests a new drug, PF-08046054/SGN-PDL1V, in people with advanced solid tumors that have spread or can't be removed. The drug is given alone or with pembrolizumab to see if it's safe and what side effects occur. About 714 participants with cancers like lung,…

This study tests a new drug, Sofetabart Mipitecan, for people with ovarian, fallopian tube, or peritoneal cancer. Part A includes those whose cancer no longer responds to platinum chemotherapy, and Part B includes those whose cancer still responds. The goal is to see if the new d…

This study tests a new drug called LY4170156 in people with advanced solid tumors, such as ovarian, lung, and breast cancers. The drug is designed to target and kill cancer cells while sparing healthy ones. The trial has two parts: first to find the safest dose, then to see how w…

This study tests a new ultrasound method called ultrasound microvessel imaging (UMI) to see if it can better detect blood flow in ovarian growths. Better blood flow detection may help doctors more accurately assess cancer risk. About 40 women scheduled for surgery for ovarian les…

This study is testing a new way to detect ovarian cancer earlier by looking at DNA from a uterine wash and proteins in the blood. Researchers will collect samples from 250 women before surgery for a suspected ovarian mass or as a preventive measure for those with BRCA mutations. …

This study tests a less invasive method called sentinel lymph node (SLN) technique in 200 women with early-stage ovarian cancer. Instead of removing many lymph nodes, doctors will check just a few key nodes for cancer spread. If the SLN technique proves accurate, it could mean fe…

This study tests a new communication tool called CASI for people with advanced ovarian cancer, their caregivers, and doctors. The goal is to see if using this tool helps patients and doctors better discuss what matters most during appointments. About 112 participants will be enro…

This study looks at how ovarian cancer affects the immune system, especially in the bone marrow and blood. Researchers will compare immune cells from 90 women with ovarian cancer to those without cancer. The goal is to find ways to retrain immune cells to better attack the tumor,…

This study is gathering tumor tissue and blood cells from 200 adults with advanced solid tumors like colorectal, lung, or pancreatic cancer. The goal is to learn how often certain genetic changes occur and to store participants' own immune cells for possible future use in making …